Humana Inc. Logo

Humana Inc.

HUM

(2.8)
Stock Price

312,00 USD

6.51% ROA

14.94% ROE

18.02x PER

Market Cap.

54.226.702.170,00 USD

70.65% DER

0.8% Yield

2.34% NPM

Humana Inc. Stock Analysis

Humana Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Humana Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (18.38%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

3 Dividend Growth

The company has demonstrated exceptional dividend growth over the past five years, consistently increasing payouts to shareholders year after year.

4 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

5 ROA

The stock's ROA (6.51%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 DER

The stock has a reasonable amount of debt compared to its ownership (71%), suggesting a balanced financial position and a moderate level of risk.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (18.372) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 PBV

The stock's elevated P/BV ratio (3.63x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

11 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Humana Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Humana Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Humana Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Humana Inc. Revenue
Year Revenue Growth
1990 4.852.000.000
1991 5.865.000.000 17.27%
1992 4.043.000.000 -45.07%
1993 3.137.000.000 -28.88%
1994 3.654.000.000 14.15%
1995 4.702.000.000 22.29%
1996 6.788.000.000 30.73%
1997 8.036.000.000 15.53%
1998 9.781.000.000 17.84%
1999 10.113.000.000 3.28%
2000 10.514.000.000 3.81%
2001 10.194.886.000 -3.13%
2002 11.261.181.000 9.47%
2003 12.226.311.000 7.89%
2004 13.104.325.000 6.7%
2005 14.418.127.000 9.11%
2006 21.416.537.000 32.68%
2007 25.289.989.000 15.32%
2008 28.946.372.000 12.63%
2009 30.960.414.000 6.51%
2010 33.868.208.000 8.59%
2011 36.832.000.000 8.05%
2012 39.126.000.000 5.86%
2013 41.313.000.000 5.29%
2014 48.500.000.000 14.82%
2015 54.289.000.000 10.66%
2016 54.379.000.000 0.17%
2017 53.767.000.000 -1.14%
2018 56.912.000.000 5.53%
2019 64.888.000.000 12.29%
2020 77.155.000.000 15.9%
2021 83.064.000.000 7.11%
2022 92.870.000.000 10.56%
2023 105.692.000.000 12.13%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Humana Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Humana Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 436.000.000 100%
1995 571.000.000 23.64%
1996 940.000.000 39.26%
1997 1.116.000.000 15.77%
1998 1.328.000.000 15.96%
1999 1.368.000.000 2.92%
2000 1.442.000.000 5.13%
2001 1.545.129.000 6.67%
2002 1.739.192.000 11.16%
2003 1.858.028.000 6.4%
2004 1.877.864.000 1.06%
2005 2.176.770.000 13.73%
2006 3.021.509.000 27.96%
2007 3.476.468.000 13.09%
2008 3.944.652.000 11.87%
2009 4.227.535.000 6.69%
2010 4.662.802.000 9.33%
2011 5.395.000.000 13.57%
2012 5.830.000.000 7.46%
2013 6.355.000.000 8.26%
2014 7.639.000.000 16.81%
2015 7.318.000.000 -4.39%
2016 7.277.000.000 -0.56%
2017 6.567.000.000 -10.81%
2018 7.525.000.000 12.73%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Humana Inc. EBITDA
Year EBITDA Growth
1990 832.300.000
1991 908.000.000 8.34%
1992 540.700.000 -67.93%
1993 197.000.000 -174.47%
1994 332.000.000 40.66%
1995 369.000.000 10.03%
1996 127.000.000 -190.55%
1997 398.000.000 68.09%
1998 378.000.000 -5.29%
1999 -247.000.000 253.04%
2000 290.000.000 185.17%
2001 379.405.000 23.56%
2002 347.916.000 -9.05%
2003 488.862.000 28.83%
2004 556.814.000 12.2%
2005 589.887.000 5.61%
2006 973.824.000 39.43%
2007 1.542.990.000 36.89%
2008 1.293.487.000 -19.29%
2009 1.957.877.000 33.93%
2010 2.117.532.000 7.54%
2011 2.647.000.000 20%
2012 2.354.000.000 -12.45%
2013 2.487.000.000 5.35%
2014 2.811.000.000 11.53%
2015 3.064.000.000 8.26%
2016 2.206.000.000 -38.89%
2017 4.747.000.000 53.53%
2018 2.826.000.000 -67.98%
2019 4.045.000.000 30.14%
2020 5.290.000.000 23.53%
2021 4.131.000.000 -28.06%
2022 4.814.000.000 14.19%
2023 5.612.000.000 14.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Humana Inc. Gross Profit
Year Gross Profit Growth
1990 4.852.000.000
1991 5.865.000.000 17.27%
1992 4.043.000.000 -45.07%
1993 3.137.000.000 -28.88%
1994 3.654.000.000 14.15%
1995 4.702.000.000 22.29%
1996 6.788.000.000 30.73%
1997 8.036.000.000 15.53%
1998 9.781.000.000 17.84%
1999 10.113.000.000 3.28%
2000 10.514.000.000 3.81%
2001 10.194.886.000 -3.13%
2002 11.261.181.000 9.47%
2003 12.226.311.000 7.89%
2004 13.104.325.000 6.7%
2005 14.418.127.000 9.11%
2006 21.416.537.000 32.68%
2007 25.289.989.000 15.32%
2008 28.946.372.000 12.63%
2009 30.960.414.000 6.51%
2010 33.868.208.000 8.59%
2011 31.437.000.000 -7.73%
2012 33.296.000.000 5.58%
2013 34.958.000.000 4.75%
2014 40.861.000.000 14.45%
2015 46.971.000.000 13.01%
2016 47.102.000.000 0.28%
2017 47.200.000.000 0.21%
2018 49.387.000.000 4.43%
2019 57.507.000.000 14.12%
2020 67.103.000.000 14.3%
2021 72.943.000.000 8.01%
2022 80.199.000.000 9.05%
2023 92.608.000.000 13.4%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Humana Inc. Net Profit
Year Net Profit Growth
1990 309.600.000
1991 355.000.000 12.79%
1992 122.700.000 -189.32%
1993 3.233.000.000 96.2%
1994 176.000.000 -1736.93%
1995 190.000.000 7.37%
1996 12.000.000 -1483.33%
1997 173.000.000 93.06%
1998 129.000.000 -34.11%
1999 -382.000.000 133.77%
2000 90.000.000 524.44%
2001 117.171.000 23.19%
2002 142.755.000 17.92%
2003 228.934.000 37.64%
2004 280.012.000 18.24%
2005 308.483.000 9.23%
2006 487.423.000 36.71%
2007 833.684.000 41.53%
2008 647.154.000 -28.82%
2009 1.039.675.000 37.75%
2010 1.099.390.000 5.43%
2011 1.419.000.000 22.52%
2012 1.222.000.000 -16.12%
2013 1.231.000.000 0.73%
2014 1.147.000.000 -7.32%
2015 1.276.000.000 10.11%
2016 614.000.000 -107.82%
2017 2.448.000.000 74.92%
2018 1.683.000.000 -45.45%
2019 2.707.000.000 37.83%
2020 3.367.000.000 19.6%
2021 2.933.000.000 -14.8%
2022 2.806.000.000 -4.53%
2023 3.328.000.000 15.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Humana Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1990 3
1991 2 -50%
1992 1 0%
1993 20 100%
1994 1 -1900%
1995 1 0%
1996 0 0%
1997 1 100%
1998 1 0%
1999 -2 100%
2000 1 0%
2001 1 0%
2002 1 0%
2003 1 100%
2004 2 0%
2005 2 0%
2006 3 50%
2007 5 60%
2008 4 -66.67%
2009 6 50%
2010 7 0%
2011 9 25%
2012 8 -14.29%
2013 8 0%
2014 7 0%
2015 9 12.5%
2016 4 -100%
2017 17 75%
2018 12 -33.33%
2019 20 40%
2020 25 20%
2021 23 -13.64%
2022 22 -4.76%
2023 27 19.23%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Humana Inc. Free Cashflow
Year Free Cashflow Growth
1990 414.100.000
1991 107.000.000 -287.01%
1992 370.000.000 71.08%
1993 157.000.000 -135.67%
1994 259.000.000 39.38%
1995 96.000.000 -169.79%
1996 269.000.000 64.31%
1997 216.000.000 -24.54%
1998 -28.000.000 871.43%
1999 128.000.000 121.88%
2000 -95.000.000 234.74%
2001 33.987.000 379.52%
2002 209.272.000 83.76%
2003 311.872.000 32.9%
2004 233.713.000 -33.44%
2005 459.781.000 49.17%
2006 1.493.561.000 69.22%
2007 985.018.000 -51.63%
2008 720.738.000 -36.67%
2009 1.236.132.000 41.69%
2010 2.019.492.000 38.79%
2011 1.743.000.000 -15.86%
2012 1.513.000.000 -15.2%
2013 1.279.000.000 -18.3%
2014 1.090.000.000 -17.34%
2015 345.000.000 -215.94%
2016 1.409.000.000 75.51%
2017 3.525.000.000 60.03%
2018 1.561.000.000 -125.82%
2019 4.548.000.000 65.68%
2020 4.675.000.000 2.72%
2021 946.000.000 -394.19%
2022 3.467.000.000 72.71%
2023 1.018.000.000 -240.57%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Humana Inc. Operating Cashflow
Year Operating Cashflow Growth
1990 758.300.000
1991 604.000.000 -25.55%
1992 674.000.000 10.39%
1993 185.000.000 -264.32%
1994 298.000.000 37.92%
1995 150.000.000 -98.67%
1996 341.000.000 56.01%
1997 289.000.000 -17.99%
1998 76.000.000 -280.26%
1999 217.000.000 64.98%
2000 40.000.000 -442.5%
2001 148.958.000 73.15%
2002 321.408.000 53.65%
2003 413.140.000 22.2%
2004 347.809.000 -18.78%
2005 625.627.000 44.41%
2006 1.686.712.000 62.91%
2007 1.224.262.000 -37.77%
2008 982.310.000 -24.63%
2009 1.421.582.000 30.9%
2010 2.241.794.000 36.59%
2011 2.079.000.000 -7.83%
2012 1.923.000.000 -8.11%
2013 1.716.000.000 -12.06%
2014 1.618.000.000 -6.06%
2015 868.000.000 -86.41%
2016 1.936.000.000 55.17%
2017 4.051.000.000 52.21%
2018 2.173.000.000 -86.42%
2019 5.284.000.000 58.88%
2020 5.639.000.000 6.3%
2021 2.262.000.000 -149.29%
2022 4.587.000.000 50.69%
2023 1.252.000.000 -266.37%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Humana Inc. Capital Expenditure
Year Capital Expenditure Growth
1990 344.200.000
1991 497.000.000 30.74%
1992 304.000.000 -63.49%
1993 28.000.000 -985.71%
1994 39.000.000 28.21%
1995 54.000.000 27.78%
1996 72.000.000 25%
1997 73.000.000 1.37%
1998 104.000.000 29.81%
1999 89.000.000 -16.85%
2000 135.000.000 34.07%
2001 114.971.000 -17.42%
2002 112.136.000 -2.53%
2003 101.268.000 -10.73%
2004 114.096.000 11.24%
2005 165.846.000 31.2%
2006 193.151.000 14.14%
2007 239.244.000 19.27%
2008 261.572.000 8.54%
2009 185.450.000 -41.05%
2010 222.302.000 16.58%
2011 336.000.000 33.84%
2012 410.000.000 18.05%
2013 437.000.000 6.18%
2014 528.000.000 17.23%
2015 523.000.000 -0.96%
2016 527.000.000 0.76%
2017 526.000.000 -0.19%
2018 612.000.000 14.05%
2019 736.000.000 16.85%
2020 964.000.000 23.65%
2021 1.316.000.000 26.75%
2022 1.120.000.000 -17.5%
2023 234.000.000 -378.63%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Humana Inc. Equity
Year Equity Growth
1990 1.749.600.000
1991 2.009.000.000 12.91%
1992 2.016.000.000 0.35%
1993 889.000.000 -126.77%
1994 1.058.000.000 15.97%
1995 1.287.000.000 17.79%
1996 1.292.000.000 0.39%
1997 1.501.000.000 13.92%
1998 1.688.000.000 11.08%
1999 1.268.000.000 -33.12%
2000 1.360.000.000 6.76%
2001 1.507.949.000 9.81%
2002 1.606.474.000 6.13%
2003 1.835.949.000 12.5%
2004 2.090.124.000 12.16%
2005 2.474.105.000 15.52%
2006 3.053.886.000 18.99%
2007 4.028.937.000 24.2%
2008 4.457.190.000 9.61%
2009 5.776.003.000 22.83%
2010 6.924.056.000 16.58%
2011 8.063.000.000 14.13%
2012 8.847.000.000 8.86%
2013 9.316.000.000 5.03%
2014 9.646.000.000 3.42%
2015 10.346.000.000 6.77%
2016 10.685.000.000 3.17%
2017 9.842.000.000 -8.57%
2018 10.161.000.000 3.14%
2019 12.037.000.000 15.59%
2020 13.728.000.000 12.32%
2021 16.103.000.000 14.75%
2022 15.370.000.000 -4.77%
2023 17.004.000.000 9.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Humana Inc. Assets
Year Assets Growth
1990 3.935.900.000
1991 4.427.000.000 11.09%
1992 3.764.000.000 -17.61%
1993 1.731.000.000 -117.45%
1994 1.957.000.000 11.55%
1995 2.878.000.000 32%
1996 3.153.000.000 8.72%
1997 5.418.000.000 41.81%
1998 5.496.000.000 1.42%
1999 4.900.000.000 -12.16%
2000 4.167.000.000 -17.59%
2001 4.403.638.000 5.37%
2002 4.600.030.000 4.27%
2003 5.293.323.000 13.1%
2004 5.657.617.000 6.44%
2005 6.869.614.000 17.64%
2006 10.127.496.000 32.17%
2007 12.879.074.000 21.36%
2008 13.041.760.000 1.25%
2009 14.153.494.000 7.85%
2010 16.103.253.000 12.11%
2011 17.708.000.000 9.06%
2012 19.979.000.000 11.37%
2013 20.735.000.000 3.65%
2014 23.466.000.000 11.64%
2015 24.705.000.000 5.02%
2016 25.396.000.000 2.72%
2017 27.178.000.000 6.56%
2018 25.413.000.000 -6.95%
2019 29.074.000.000 12.59%
2020 34.969.000.000 16.86%
2021 44.343.000.000 21.14%
2022 43.055.000.000 -2.99%
2023 55.905.000.000 22.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Humana Inc. Liabilities
Year Liabilities Growth
1990 2.186.300.000
1991 2.418.000.000 9.58%
1992 1.748.000.000 -38.33%
1993 842.000.000 -107.6%
1994 899.000.000 6.34%
1995 1.591.000.000 43.49%
1996 1.861.000.000 14.51%
1997 3.917.000.000 52.49%
1998 3.808.000.000 -2.86%
1999 3.632.000.000 -4.85%
2000 2.807.000.000 -29.39%
2001 2.895.689.000 3.06%
2002 2.993.556.000 3.27%
2003 3.457.374.000 13.42%
2004 3.567.493.000 3.09%
2005 4.395.509.000 18.84%
2006 7.073.610.000 37.86%
2007 8.850.137.000 20.07%
2008 8.584.570.000 -3.09%
2009 8.377.491.000 -2.47%
2010 9.179.197.000 8.73%
2011 9.645.000.000 4.83%
2012 11.132.000.000 13.36%
2013 11.419.000.000 2.51%
2014 13.820.000.000 17.37%
2015 14.359.000.000 3.75%
2016 14.711.000.000 2.39%
2017 17.336.000.000 15.14%
2018 15.252.000.000 -13.66%
2019 17.037.000.000 10.48%
2020 21.241.000.000 19.79%
2021 28.240.000.000 24.78%
2022 27.685.000.000 -2%
2023 38.901.000.000 28.83%

Humana Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
829.25
Net Income per Share
24.44
Price to Earning Ratio
18.02x
Price To Sales Ratio
0.53x
POCF Ratio
9.08
PFCF Ratio
10.83
Price to Book Ratio
3.21
EV to Sales
0.5
EV Over EBITDA
9.98
EV to Operating CashFlow
8.53
EV to FreeCashFlow
10.19
Earnings Yield
0.06
FreeCashFlow Yield
0.09
Market Cap
54,23 Bil.
Enterprise Value
51,05 Bil.
Graham Number
274.82
Graham NetNet
-58.66

Income Statement Metrics

Net Income per Share
24.44
Income Quality
1.99
ROE
0.18
Return On Assets
0.05
Return On Capital Employed
0.14
Net Income per EBT
0.74
EBT Per Ebit
0.84
Ebit per Revenue
0.04
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.88
Operating Profit Margin
0.04
Pretax Profit Margin
0.03
Net Profit Margin
0.02

Dividends

Dividend Yield
0.01
Dividend Yield %
0.8
Payout Ratio
0.14
Dividend Per Share
3.54

Operating Metrics

Operating Cashflow per Share
48.51
Free CashFlow per Share
40.58
Capex to Operating CashFlow
-0.16
Capex to Revenue
-0.01
Capex to Depreciation
-1.09
Return on Invested Capital
0.12
Return on Tangible Assets
0.07
Days Sales Outstanding
6.5
Days Payables Outstanding
294.82
Days of Inventory on Hand
0
Receivables Turnover
56.11
Payables Turnover
1.24
Inventory Turnover
0
Capex per Share
-7.93

Balance Sheet

Cash per Share
245,43
Book Value per Share
137,32
Tangible Book Value per Share
60.47
Shareholders Equity per Share
137.32
Interest Debt per Share
100.7
Debt to Equity
0.71
Debt to Assets
0.21
Net Debt to EBITDA
-0.62
Current Ratio
1.37
Tangible Asset Value
7,46 Bil.
Net Current Asset Value
-0,65 Bil.
Invested Capital
0.71
Working Capital
10,43 Bil.
Intangibles to Total Assets
0.17
Average Receivables
1,63 Bil.
Average Payables
18,11 Bil.
Average Inventory
0
Debt to Market Cap
0.22

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Humana Inc. Dividends
Year Dividends Growth
1982 1
1983 1 0%
1984 1 0%
1985 1 0%
1986 1 0%
1987 1 0%
1988 1 0%
1989 1 100%
1990 1 0%
1991 1 0%
1992 1 0%
1993 14 100%
2011 1 0%
2012 1 100%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 2 100%
2018 2 50%
2019 2 0%
2020 3 0%
2021 3 0%
2022 3 33.33%
2023 4 0%

Humana Inc. Profile

About Humana Inc.

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

CEO
Mr. Bruce Dale Broussard
Employee
67.600
Address
Humana Building
Louisville, 40202

Humana Inc. Executives & BODs

Humana Inc. Executives & BODs
# Name Age
1 Mr. James A. Rechtin M.B.A.
President & Chief Operating Officer
70
2 Mr. Samir M. Deshpande
Chief Information Officer
70
3 Mr. Joseph C. Ventura
Chief Legal Officer
70
4 Dr. Sanjay K. Shetty M.B.A., M.D.
President of CenterWell
70
5 Mr. Eric Tagliere
Senior Vice President & Chief Technology Officer
70
6 Mr. George Renaudin II
President of Medicare & Medicaid
70
7 Mr. Timothy S. Huval
Chief Administrative Officer
70
8 Mr. Bruce Dale Broussard
Chief Executive Officer & Director
70
9 Mr. John-Paul William Felter
Senior Vice President, Chief Accounting Officer, Principal Accounting Officer & Controller
70
10 Ms. Susan Marie Diamond
Chief Financial Officer
70

Humana Inc. Competitors